Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 7;22:67. doi: 10.1186/s12865-021-00459-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — The influence of TLR2 activation on inhibitory molecules expression in peripheral and tumor-infiltrating CD8⁺ T cells from NC and GC patients. CD8⁺ T cells were purified from the same subjects as in Fig. 2, including peripheral bloods of NC (n = 9) and GC patients (n = 11), as well as from tumor residency of GC patients (n = 11), and were cultured for 12 h in the presence of anti-CD3/CD28 with or without TLR2 agonist Pam3Csk4. Lymphocyte activation gene-3 (LAG-3) and CD279 (programmed death-1, PD-1) expression in CD8⁺ T cells was measured by flow cytometry. a The representative flow dots of LAG-3 and PD-1 positive cells in peripheral CD8⁺ T cells from NC and GC patients, as well as in tumor-infiltrating CD8⁺ T cells from GC patents with or without Pam3Csk4 stimulation. The percentage of b LAG-3⁺ and c PD-1⁺ cells within CD8⁺ T cells was compared. The columns indicated means, and the bars indicated standard deviation. Significances were determined by LSD-t test or paired t test